Celltrion wins a series of government bids from Singapore and Malaysia
Celltrion wins a series of government bids from Singapore and Malaysia
  • Kim Min-jee
  • 승인 2019.12.24 11:39
  • 댓글 0
이 기사를 공유합니다

Direct sales system of Remsima, Herzuma cruises in Asia, including Thailand
Celltrion Chairman Suh Jung-jin

Celltrion Healthcare, which is in charge of overseas sales of Celltrion products, has won successive government bids in Asia, including Singapore and Malaysia.

Celltrion Healthcare announced on Dec. 23 that it participated in the government’s bid for the autoimmune disease treatment Remsima (Infliximab) held in Singapore in the third quarter, winning the order for the third consecutive year.

Accordingly, Celltrion Healthcare will exclusively supply Remsima to the Health Cluster, which accounts for 90 percent of the infleximab market, in 2020, following this year.

Celltrion Healthcare also won a bid from the Malaysian government to expand its Remsima market. Until now, Remsima had been selling only in the private insurance market, which accounts for half of the Malaysian market. The successful bid this time, however, will also allow the company to make inroads into the public insurance market.

In particular, Celltrion Healthcare expected that the bidding results will have a positive impact on neighboring Asian countries such as Brunei, saying that winning the bids from Singapore and Malaysia is the result of successful direct sales.

At the same time, Celltrion explained that it succeeded in winning the order by beating its rival products with "Herzuma (Trastuzumab)" in a government bid for breast and stomach cancer treatment in Thailand in October.

The bid is equivalent to 40 percent of Thailand's Trastuzumab market. Through the bidding, Celltrion Healthcare will exclusively supply Herzuma to Thailand's state-run hospitals for one year from March next year.

A Celltrion Healthcare official stressed that winning the bids from the three nations is a significant achievement that has once again demonstrated the company’s global direct selling capabilities.

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.

  • #1206, 36-4 Yeouido-dong, Yeongdeungpo-gu, Seoul, Korea(Postal Code 07331)
  • 서울특별시 영등포구 여의도동 36-4 (국제금융로8길 34) / 오륜빌딩 1206호
  • URL: www.koreaittimes.com / m.koreaittimes.com. Editorial Div. 02-578-0434 / 010-2442-9446. Email: info@koreaittimes.com.
  • Publisher: Monica Younsoo Chung. Chief Editorial Writer: Kim Hyoung-joong. CEO: Lee Kap-soo. Editor: Jung Yeon-jin.
  • Juvenile Protection Manager: Yeon Choul-woong. IT Times Canada: Willow St. Vancouver BC, Canada / 070-7008-0005.
  • Copyright(C) Korea IT Times, Allrights reserved.